Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: Association with insulin resistance

Journal of Cardiology

Volumn 58, Issue 1, 2011, Pages 18-25

  Shigematsu, Yuji ^a   Hamada, Mareomi ^b   Nagai, Takayuki ^a   Nishimura, Kazuhisa ^a   Inoue, Katsuji ^a   Suzuki, Jun ^a   Ogimoto, Akiyoshi ^a   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Uwajima City Hospital   (Japan)

Author keywords

Atrial fibrillation; Hypertrophic cardiomyopathy; Insulin resistance; Left atrial size; Left ventricular diastolic function

Indexed keywords

ANTIARRHYTHMIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD FLOW VELOCITY; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE FILLING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INSULIN RESISTANCE; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SINUS RHYTHM; TRIACYLGLYCEROL BLOOD LEVEL; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AGED; ATRIAL FIBRILLATION; CARDIOMYOPATHY, HYPERTROPHIC; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; NATRIURETIC PEPTIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79959685824     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.03.001     Document Type: Article

References (45)

1. Cecchi F., Olivotto I., Montereggi A., Santoro G., Dolara A., Maron B.J. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995, 26:1529-1536.
2. Maron B.J. Hypertrophic cardiomyopathy. Lancet 1997, 350:127-133.
3. Spirito P., Seidman C.E., McKenna W.J., Maron B.J. The management of hypertrophic cardiomyopathy. N Engl J Med 1997, 336:775-785.
4. Kubo T., Kitaoka H., Okawa M., Hirota T., Hayato K., Yamasaki N., Matsumura Y., Yabe T., Doi Y.L. Gender-specific differences in the clinical features of hypertrophic cardiomyopathy in a community-based Japanese population: results from Kochi RYOMA study. J Cardiol 2010, 56:314-319.
5. Shigematsu Y., Hamada M., Mukai M., Mastuoka H., Sumimoto T., Hiwada K. Mechanism of atrial fibrillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy. Jpn Circ J 1995, 59:329-336.
6. Maron B.J., Olivotto I., Bellone P., Conte M.R., Cecchi F., Flygenring B.P., Casey S.A., Gohman T.E., Bongioanni S., Spirito P. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 39:301-307.
7. Olivotto I., Cecchi F., Casey S.A., Dolara A., Traverse J.H., Maron B.J. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001, 104:2517-2524.
8. Prystowky E., Waldo A. Atrial fibrillation, atrial flutter, and atrial tachycardia. Hurst's the heart 2008, 953-982. McGraw-Hill, New York. 12th ed. V. Fuster, R. O'Rourke, R. Walsh, P. Poole-Wilson (Eds.).
9. Swan J.W., Anker S.D., Walton C., Godsland I.F., Clark A.L., Leyva F., Stevenson J.C., Coats A.J.S. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997, 30:527-532.
10. Wisniacki N., Taylor W., Lye M., Wilding J.P.H. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 2005, 91:32-37.
11. Wigle E.D., Sasson Z., Henderson M.A., Ruddy T.D., Fulop J., Rakowski H., Williams W.G. Hypertrophic cardiomyopathy. The importance of the site and extent of hypertrophy. A review. Prog Cardiovasc Dis 1985, 28:1-83.
12. Spirito P., Maron B.J. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990, 15:808-813.
13. Murakami K., Shigematsu Y., Hamada M., Higaki J. Insulin resistance in patients with hypertrophic cardiomyopathy. Circ J 2004, 68:650-655.
14. Wang T.J., Parise H., Levy D., D'Agostino R.B., Wolf P.A., Vasan R.S., Benjamin E.J. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004, 292:2471-2477.
15. Dublin S., French B., Glazer N.L., Wiggins K.L., Lumley T., Psaty B.M., Smith N.L., Heckbert S.R. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006, 166:2322-2328.
16. Watanabe H., Tanabe N., Watanabe T., Darber D., Roden D.M., Sasaki S., Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation. The Niigata Preventive Medicine Study. Circulation 2008, 117:1255-1260.
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
18. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I., Martin I., Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996, 93:841-842.
19. Hamada M., Shigematsu Y., Ikeda S., Hara Y., Okayama H., Kodama K., Ochi T., Hiwada K. Class Ia antiarrhythmic drug cibenzoline. A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997, 96:1520-1524.
20. Hamada M., Kawakami H., Shigematsu Y., Minamino N., Kangawa K., Matsuo H., Hiwada K. Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: its relation to endothelin-1, natriuretic peptides and noradrenaline. Clin Sci 1998, 94:21-28.
21. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419.
22. Shigematsu Y., Norimatsu S., Ogimoto A., Ohtsuka T., Okayama H., Higaki J. The influence of insulin resistance and obesity on left atrial size in Japanese hypertensive patients. Hypertens Res 2009, 32:500-504.
23. Sahn D.J., DeMaria A., Kisslo J., Weyman A. The Committee on M-Mode Standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978, 58:1072-1083.
24. Sasson Z., Yock P.G., Hatle L.K., Alderman E.L., Popp R.L. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. J Am Coll Cardiol 1988, 11:752-756.
25. Nagueh S.F., Sun H., Kopelen H.A., Middleton K.J., Khoury D.S. Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J Am Coll Cardiol 2001, 37:278-285.
26. Nagueh S.F., Middleton K.J., Kopelen H.A., Zoghbi W.A., Quinones M.A. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997, 30:1527-1533.
27. Ruige J.B., Assendelft W.J.J., Dekker J.M., Kostense P.J., Heine R.J., Bouter L.M. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998, 97:996-1001.
28. Verdecchia P., Reboldi G., Schillaci G., Borgioni C., Ciucci A., Telera M.P., Santeusanio F., Porcellati C., Brunetti P. Circulating insulin and insulin insulin-like growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999, 100:1802-1807.
29. Ito H., Hiroe M., Hirata Y., Tsujino M., Adachi S., Shichiri M., Koike A., Nogami A., Marumo F. Insulin-like growth factor-1 induces cardiac hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circulation 1993, 87:1715-1721.
30. Marian A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000, 355:58-60.
31. Rask-Madsen C., Dominguez N., Ihlemann N., Hermann T., Kober L., Torp-Pedersen C. Tumor necrosis factor-α inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 2003, 108:1815-1821.
32. Gerdts E., Oikarinen L., Palmieri V., Otterstad J.E., Wachtell K., Boman K., Dahlöf B., Devereux R.B. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002, 39:739-743.
33. Yang H., Woo A., Monakier D., Jamorski M., Fedwick K., Wigle D., Rakowski H. Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. J Am Soc Echocardiogr 2005, 18:1074-1082.
34. Nicolaou V.N., Papadakis J.E., Karatzis E.N., Dermitzaki S.I., Tsakiris A.K., Skoufas P.D. Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation. Angiology 2007, 58:21-25.
35. Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Carnes C.A., Bauer J.A., Tchou P.J., Niebauer M.J., Natale A., Van Wagoner D.R. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001, 104:2886-2891.
36. Mihm M.J., Yu F., Carnes C.A., Reiser P.J., McCarthy P.M., Van Wagoner D.R., Bauer J.A. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001, 104:174-180.
37. Savage D., Petersen K.F., Shulman G.I. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005, 45:828-833.
38. Vaziri S.M., Larson M.G., Lauer M.S., Benjamin E.J., Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension 1995, 25:1155-1160.
39. Hamada M., Shigematsu Y., Hara Y., Suzuki M., Ohtsuka T., Hiasa G., Ogimoto A., Saeki H., Suzuki J., Hiwada K. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Circ J 2001, 65:531-538.
40. Nishimura R.A., Appleton C.P., Redfield M.M., Ilstrup D.M., Holmes D.R., Tajik J. Noninvasive Doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol 1996, 28:1226-1233.
41. Matsumura Y., Elliott P.M., Virdee M.S., Sorajja P., Doi Y.L., McKenna W.J. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart 2002, 87:247-251.
42. Kitaoka H., Kubo T., Okawa M., Hirota T., Hayato K., Yamasaki N., Matsumura Y., Doi Y.L. Utility of tissue Doppler imaging to predict exercise capacity in hypertrophic cardiomyopathy: comparison with B-type natriuretic peptide. J Cardiol 2009, 53:361-367.
43. Haissaguerre M., Jais P., Shah D.C., Takahashi A., Hocini M., Quinion G., Garrigue S., Mouroux A.L., Metayer P.L., Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998, 339:659-666.
44. Lubien E., DeMaria A., Krishnaswamy P., Clopton P., Koon J., Kazanegra R., Gardetto N., Wanner E., Maisel A.S. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002, 105:595-601.
45. Baba O., Izuhara M., Kadota S., Mitsuoka H., Shioji K., Uegaito T., Mutsuo S., Matsuda M. Determinant factors of plasma B-type natriuretic peptide levels in patients with persistent nonvalvular atrial fibrillation and preserved left ventricular systolic function. J Cardiol 2009, 54:402-408.